



# GENMAB'S HUMAX-HEPC PREVENTS HEPATITIS C VIRUS INFECTION IN ANIMAL MODEL

## About Hepatitis C virus (HCV)

Worldwide more than 170 million people are chronically infected with HCV, including approximately 3.9 million in the United States and 8.9 million in Europe. Most infected people develop increasing liver fibrosis over time that can lead to cirrhosis, liver failure or liver cancer. From population-based studies it is estimated that in the United States 8,000–10,000 deaths occur each year due to HCV-related chronic liver disease. Moreover, Hepatitis C is the main cause of about half of the estimated 10,000 liver transplants in Europe and the United States each year. A major complication of liver transplantation in HCV-patients is re-infection of the graft by HCV. Studies conducted in several laboratories support the rationale for using antibodies to prevent liver infection or re-infection with HCV.

## About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody™, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. For more information about Genmab, visit [www.genmab.com](http://www.genmab.com).

*This press release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.*

Genmab®, the Y-shaped Genmab logo®, HuMax®, HuMax-CD4®, HuMax-EGFr™, HuMax-Inflam™, HuMax-CD20™, HuMax-TAC™, HuMax-HepC™, HuMax-CD38™, HuMax-ZP3™, and UniBody™ are all trademarks of Genmab A/S.

###